靶向递送CD34适配体偶联托珠单抗微球有效治疗甲状腺相关眼病
本研究将聚乳酸-羟基乙酸共聚物微球与CD34特异性适配体偶联,增强托珠单抗对CD34+眼眶成纤维细胞的靶向递送。体外实验显示该体系可抑制TGF-β1刺激的CD34+眼眶成纤维细胞活力、增殖、活化、细胞外基质蛋白表达和迁移;体内TAO小鼠模型显示组织炎症、纤维化和ECM蛋白水平显著降低,并明显抑制STAT3信号通路。
要点
- CD34适配体对CD34+眼眶成纤维细胞具有高特异性和结合强度
- Toc-MS-CD34 Apt在体外抑制TGF-β1刺激的CD34+眼眶成纤维细胞活力、增殖、活化和迁移
- TAO小鼠模型显示抗小鼠IL-6R微球及CD34适配体修饰版本均显著减少组织炎症、纤维化和ECM蛋白
核心结论
- CD34适配体偶联托珠单抗微球有望成为甲状腺相关眼病的靶向治疗策略,提供针对疾病局部表现的综合策略。
研究设计与样本
- 研究采用PLGA微球偶联CD34特异性适配体递送托珠单抗至CD34+眼眶成纤维细胞,并进行体外细胞实验和TAO小鼠模型体内实验。
主要发现
- CD34适配体对CD34+眼眶成纤维细胞具有高特异性和结合强度。
- Toc-MS-CD34 Apt尺寸均一且适配体偶联成功。
- 体外Toc-MS-CD34 Apt有效抑制TGF-β1刺激的CD34+眼眶成纤维细胞活力、增殖、细胞活化、ECM蛋白表达和迁移。
- 体内TAO小鼠模型经抗小鼠IL-6R微球和CD34适配体修饰的抗小鼠IL-6R微球治疗后,组织炎症、纤维化和ECM蛋白水平显著降低,STAT3信号通路明显抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Thyroid-associated ophthalmopathy (TAO) is a debilitating autoimmune disorder linked to Graves' disease (GD) that is characterized by inflammation and remodeling of orbital tissues. This study focuses on the use of poly(lactic-co-glycolic) acid (PLGA)-based microspheres (MS) coupled with CD34-specific aptamers to enhance the targeted delivery of Tocilizumab (Toc), an IL-6 receptor monoclonal antibody, to CD34+ orbital fibroblasts, which is a critical cell type implicated in TAO. METHODS: The flow cytometry and aptamer-mediated pull-down assays were applied to detect the affinity of CD34 aptamers (Apts) for CD34+ orbital fibroblasts. The CD34 Apt-modified Toc-loaded MS (Toc-MS-CD34 Apt) were characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FT-IR), and agarose gel electrophoresis. The CCK-8 assay kit was used to examine cell viability. The EdU assay was used to assess cell proliferation. The scratch wound healing assay was applied to detect cell migration. RESULTS: The affinity of CD34 aptamers for CD34+ orbital fibroblasts was confirmed, demonstrating high specificity and binding strength. The Toc-MS-CD34 Apt exhibited size uniformity and successful aptamer conjugation. In vitro, studies showed that Toc-MS-CD34 Apt effectively inhibited the viability, proliferation and cell activation, extracellular matrix (ECM) protein expression, and migration of TGF-β1-stimulated CD34+ orbital fibroblasts. In vivo, a TAO mouse model treated with anti-mouse IL-6R microspheres (anti-mmu-IL-6R-MS) and CD34 aptamer-modified anti-mmu-IL-6R microspheres (anti-mmu-IL-6R-MS-CD34 Apt) demonstrated significant reductions in tissue inflammation, fibrosis, and ECM protein levels, with notable inhibition of the STAT3 signaling pathway. CONCLUSIONS: These findings highlight the potential of CD34 aptamer-coupled Toc microspheres as a targeted therapy for TAO, providing a comprehensive strategy that addresses local manifestations of the disease.
引用
- Luo Y, Yin J, Cao J, et al. Targeted Delivery of CD34 Aptamer-Coupled Tocilizumab Microspheres for Effective Treatment of Thyroid-Associated Ophthalmopathy. Invest Ophthalmol Vis Sci. 2025. PMID: 40853309. doi:10.1167/iovs.66.11.57
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。